JP2009522255A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009522255A5 JP2009522255A5 JP2008548427A JP2008548427A JP2009522255A5 JP 2009522255 A5 JP2009522255 A5 JP 2009522255A5 JP 2008548427 A JP2008548427 A JP 2008548427A JP 2008548427 A JP2008548427 A JP 2008548427A JP 2009522255 A5 JP2009522255 A5 JP 2009522255A5
- Authority
- JP
- Japan
- Prior art keywords
- isokisazo
- carboxylic acid
- amide
- ethyl
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 claims 28
- -1 carboalkoxy group Chemical group 0.000 claims 12
- IDWZESHNJMMWTR-UHFFFAOYSA-N 2-(1,2,4-triazol-1-yl)ethanamine Chemical compound NCCN1C=NC=N1 IDWZESHNJMMWTR-UHFFFAOYSA-N 0.000 claims 8
- YCIRHAGYEUJTFH-UHFFFAOYSA-N 2-imidazol-1-ylethanamine Chemical compound NCCN1C=CN=C1 YCIRHAGYEUJTFH-UHFFFAOYSA-N 0.000 claims 8
- IXXJEYNOJZNYBD-UHFFFAOYSA-N 3-(1,2,4-triazol-1-yl)propan-1-amine Chemical compound NCCCN1C=NC=N1 IXXJEYNOJZNYBD-UHFFFAOYSA-N 0.000 claims 8
- DSTFTYAYSLZREG-UHFFFAOYSA-N 2-(triazol-2-yl)ethanamine Chemical compound NCCN1N=CC=N1 DSTFTYAYSLZREG-UHFFFAOYSA-N 0.000 claims 6
- UIWDESVQLUNCRV-UHFFFAOYSA-N 2-pyrazol-1-ylethanamine Chemical compound NCCN1C=CC=N1 UIWDESVQLUNCRV-UHFFFAOYSA-N 0.000 claims 6
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- CHEYEJGXQSHSFE-UHFFFAOYSA-N 2-(triazol-1-yl)ethanamine Chemical compound NCCN1C=CN=N1 CHEYEJGXQSHSFE-UHFFFAOYSA-N 0.000 claims 4
- 150000002545 isoxazoles Chemical class 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000000126 substance Substances 0.000 claims 3
- NYYJJFZSMLAAQM-UHFFFAOYSA-N 2-(4-methylimidazol-1-yl)ethanamine Chemical compound CC1=CN(CCN)C=N1 NYYJJFZSMLAAQM-UHFFFAOYSA-N 0.000 claims 2
- IJNXVZYBHJQPRM-UHFFFAOYSA-N 2-(5-methylimidazol-1-yl)ethanamine Chemical compound CC1=CN=CN1CCN IJNXVZYBHJQPRM-UHFFFAOYSA-N 0.000 claims 2
- ZGHVPBISEIPFJS-UHFFFAOYSA-N 2-(tetrazol-1-yl)ethanamine Chemical compound NCCN1C=NN=N1 ZGHVPBISEIPFJS-UHFFFAOYSA-N 0.000 claims 2
- MVUXXHVOQXOIKY-UHFFFAOYSA-N 2-(tetrazol-2-yl)ethanamine Chemical compound NCCN1N=CN=N1 MVUXXHVOQXOIKY-UHFFFAOYSA-N 0.000 claims 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 2
- TUVONOFKFDJHBJ-UHFFFAOYSA-N 2-pyridin-2-yloxyethanamine Chemical compound NCCOC1=CC=CC=N1 TUVONOFKFDJHBJ-UHFFFAOYSA-N 0.000 claims 2
- NAHHNSMHYCLMON-UHFFFAOYSA-N 2-pyridin-3-ylethanamine Chemical compound NCCC1=CC=CN=C1 NAHHNSMHYCLMON-UHFFFAOYSA-N 0.000 claims 2
- UGYXACYDHGNSFL-UHFFFAOYSA-N 3-(tetrazol-1-yl)propan-1-amine Chemical compound NCCCN1C=NN=N1 UGYXACYDHGNSFL-UHFFFAOYSA-N 0.000 claims 2
- MRAPXKXFUVKPFR-UHFFFAOYSA-N 3-(triazol-1-yl)propan-1-amine Chemical compound NCCCN1C=CN=N1 MRAPXKXFUVKPFR-UHFFFAOYSA-N 0.000 claims 2
- SXJKZCLYUDXHSD-UHFFFAOYSA-N 3-(triazol-2-yl)propan-1-amine Chemical compound NCCCN1N=CC=N1 SXJKZCLYUDXHSD-UHFFFAOYSA-N 0.000 claims 2
- JSXVMXHCFBPCLV-UHFFFAOYSA-N 3-pyrazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CC=N1 JSXVMXHCFBPCLV-UHFFFAOYSA-N 0.000 claims 2
- IMCKMDQAPIFXAK-UHFFFAOYSA-N 5-thiophen-2-yl-n-[3-(1,2,4-triazol-1-yl)propyl]-1,2-oxazole-3-carboxamide Chemical compound C1=C(C=2SC=CC=2)ON=C1C(=O)NCCCN1C=NC=N1 IMCKMDQAPIFXAK-UHFFFAOYSA-N 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000004149 thio group Chemical group *S* 0.000 claims 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 125000004112 carboxyamino group Chemical group [H]OC(=O)N([H])[*] 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2005-0135247 | 2005-12-30 | ||
| KR20050135247 | 2005-12-30 | ||
| KR1020060135390A KR101394245B1 (ko) | 2005-12-30 | 2006-12-27 | 아이속사졸 유도체 및 이의 용도 |
| KR10-2006-0135390 | 2006-12-27 | ||
| PCT/KR2006/005837 WO2007078113A1 (en) | 2005-12-30 | 2006-12-28 | Isoxazole derivatives and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009522255A JP2009522255A (ja) | 2009-06-11 |
| JP2009522255A5 true JP2009522255A5 (enExample) | 2010-02-12 |
| JP5246499B2 JP5246499B2 (ja) | 2013-07-24 |
Family
ID=38507387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008548427A Active JP5246499B2 (ja) | 2005-12-30 | 2006-12-28 | イソキサゾール誘導体及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7915297B2 (enExample) |
| EP (1) | EP1971600B1 (enExample) |
| JP (1) | JP5246499B2 (enExample) |
| KR (1) | KR101394245B1 (enExample) |
| ES (1) | ES2436103T3 (enExample) |
| WO (1) | WO2007078113A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2640531C (en) | 2006-01-27 | 2017-01-03 | The Regents Of The University Of California | Enterically coated cysteamine, cystamine and derivatives thereof |
| JP5205274B2 (ja) * | 2006-11-22 | 2013-06-05 | 日本農薬株式会社 | 新規なピラゾール誘導体、有害生物防除剤及びその使用方法 |
| ATE539078T1 (de) * | 2007-06-29 | 2012-01-15 | Sk Holdings Co Ltd | Isoxazolderivate enthaltende pharmazeutische zusammensetzung zur prävention und behandlung von restenose |
| US12404304B1 (en) | 2007-11-14 | 2025-09-02 | Sierra Sciences, Llc | Telomerase reverse transcriptase (TERT) expression enhancing compounds and methods for using the same |
| TWI450898B (zh) * | 2008-07-04 | 2014-09-01 | Sigma Tau Res Switzerland Sa | 具有抗腫瘤活性之芳基異唑化合物 |
| CA2764339A1 (en) | 2009-06-05 | 2010-12-09 | Oslo University Hospital Hf | Azole derivatives as wtn pathway inhibitors |
| WO2011084642A1 (en) * | 2009-12-16 | 2011-07-14 | Neuropore Therapies, Inc. | Compound suitable for the treatment of synucleopathies |
| JP5996532B2 (ja) | 2010-07-15 | 2016-09-21 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | 有害生物防除剤としての新規複素環式化合物 |
| WO2012076898A1 (en) * | 2010-12-08 | 2012-06-14 | Oslo University Hospital Hf | Triazole derivatives as wnt signaling pathway inhibitors |
| AU2012340622A1 (en) | 2011-11-23 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | Isoxazole treatments for diabetes |
| AU2014302458A1 (en) * | 2013-06-26 | 2015-12-24 | Proteostasis Therapeutics, Inc. | Methods of modulating CFTR activity |
| EP3116501A1 (en) | 2014-03-13 | 2017-01-18 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| WO2015138934A1 (en) | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| CA2952862A1 (en) | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
| US9505729B2 (en) * | 2014-08-22 | 2016-11-29 | Vanderbilt University | Isoxazole analogs as mediators of transcriptional induction of E-cadherin |
| US9783510B2 (en) | 2014-08-22 | 2017-10-10 | Vanderbilt University | Small molecule mediated transcriptional induction of E-cadherin |
| CN109251894B (zh) | 2014-11-25 | 2022-10-04 | 宾州研究基金会 | 人神经胶质细胞转化成用于大脑和脊髓修复的神经细胞的化学重编程 |
| WO2016095205A1 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Heteroaryl orexin receptor antagonists |
| MA41253A (fr) | 2014-12-23 | 2017-10-31 | Proteostasis Therapeutics Inc | Composés, compositions et procédés pour augmenter l'activité du cftr |
| CA2971850A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| CA2971835A1 (en) * | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| CA2971855A1 (en) | 2014-12-23 | 2016-06-30 | Proteostasis Therapeutics, Inc. | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis |
| WO2016101118A1 (en) * | 2014-12-23 | 2016-06-30 | Merck Sharp & Dohme Corp. | Amidoethyl azole orexin receptor antagonists |
| AU2016297886B2 (en) | 2015-07-24 | 2020-12-10 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing CFTR activity |
| KR20180093882A (ko) | 2015-10-06 | 2018-08-22 | 프로테오스타시스 테라퓨틱스, 인크. | Cftr 조절용 화합물, 조성물, 및 방법 |
| CN109563047A (zh) | 2016-04-07 | 2019-04-02 | 蛋白质平衡治疗股份有限公司 | 含有硅原子的依伐卡托类似物 |
| ES2954658T3 (es) | 2016-06-21 | 2023-11-23 | Proteostasis Therapeutics Inc | Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR |
| US20220409590A1 (en) * | 2019-11-25 | 2022-12-29 | The Penn State Research Foundation | Chemotherapy for glioma through neuronal conversion |
| KR102500978B1 (ko) * | 2021-05-10 | 2023-02-17 | 조성은 | 이속사졸 유도체를 포함하는 탈모 완화 및 발모 촉진용 조성물 |
| JP2024520269A (ja) * | 2021-05-18 | 2024-05-24 | ユニバーシティ オブ サザン カリフォルニア | ヒト顆粒球／マクロファージ前駆体の増殖方法及びその用途 |
| CN115677608B (zh) * | 2022-09-08 | 2024-06-07 | 复旦大学 | 苯并异噁唑-3-甲酰胺类化合物及其合成和应用 |
| KR102787749B1 (ko) * | 2022-12-29 | 2025-03-31 | 중앙대학교 산학협력단 | 비스이소옥사졸 화합물을 유효성분으로 함유하는 퇴행성 뇌질환 예방 또는 치료용 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH475301A (de) | 1964-10-27 | 1969-07-15 | Ciba Geigy | Verfahren zur Herstellung von mit Oxazolverbindungen optisch aufgehellten Formkörpern |
| FR2073284B1 (enExample) * | 1969-12-23 | 1973-07-13 | Ferlux | |
| BE795808A (fr) | 1972-02-24 | 1973-08-22 | Beecham Group Ltd | Amidazoles polysubstitues |
| US3852293A (en) | 1972-06-21 | 1974-12-03 | Uniroyal Inc | 4-phenyl-2-(3-pyridyl)-thiazole carboxamides |
| GB1492663A (en) | 1975-02-20 | 1977-11-23 | Lepetit Spa | 4-amino-3-pyrrole carboxamides |
| JPS568352A (en) * | 1979-07-03 | 1981-01-28 | Shionogi & Co Ltd | Aminoalkylvenzene derivative |
| JPS6143191A (ja) * | 1984-08-07 | 1986-03-01 | Kyorin Pharmaceut Co Ltd | イミダゾ〔１，５−ａ〕ピリミジン誘導体 |
| US5201932A (en) * | 1989-09-22 | 1993-04-13 | Basf Aktiengesellschaft | Carboxamides |
| DE3932052A1 (de) | 1989-09-26 | 1991-04-04 | Basf Ag | Oxazol- bzw. thiazolcarbonsaeureamide |
| DE4201047A1 (de) * | 1992-01-17 | 1993-07-22 | Bayer Ag | Substituierte isoxazolcarbonsaeureamide |
| ATE217865T1 (de) | 1994-06-24 | 2002-06-15 | Euro Celtique Sa | Verbindungen zur hemmung von phosphodiesrerase iv |
| JP3542827B2 (ja) * | 1994-07-15 | 2004-07-14 | 帝国臓器製薬株式会社 | 新規な５−置換イソキサゾール−３−カルボン酸アミド誘導体 |
| EP0726263A3 (en) | 1995-02-08 | 1996-10-09 | American Cyanamid Co | Herbicides (1,3,4) oxadiazoles and thiadiazoles |
| TWI262185B (en) * | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| ATE335737T1 (de) * | 2000-09-15 | 2006-09-15 | Vertex Pharma | Isoxazole und ihre verwendung als erk-inhibitoren |
| JPWO2002080899A1 (ja) * | 2001-03-30 | 2005-01-06 | エーザイ株式会社 | 消化器疾患治療剤 |
| JP4549021B2 (ja) * | 2001-03-30 | 2010-09-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ベンゼン化合物およびその塩 |
| JPWO2002098840A1 (ja) * | 2001-06-04 | 2004-09-16 | エーザイ株式会社 | カルボン酸誘導体及びその塩もしくはそのエステルからなる医薬 |
| TW591020B (en) | 2001-06-20 | 2004-06-11 | Wyeth Corp | 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| JP2005501073A (ja) | 2001-08-06 | 2005-01-13 | フアルマシア・イタリア・エツセ・ピー・アー | キナーゼ阻害薬活性を有するアミノイソオキサゾール誘導体 |
| AR034897A1 (es) | 2001-08-07 | 2004-03-24 | Hoffmann La Roche | Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos |
| WO2003016265A1 (en) * | 2001-08-17 | 2003-02-27 | Eisai Co., Ltd. | Cyclic compound and ppar agonist |
| CA2515235A1 (en) * | 2003-02-10 | 2004-08-19 | Bayer Healthcare Ag | Bis(hetero)aryl carboxamide derivatives for use as pgi2 antagonists |
| DE102004051277A1 (de) | 2004-10-21 | 2006-04-27 | Merck Patent Gmbh | Heterocyclische Carbonylverbindungen |
| JP2006176443A (ja) * | 2004-12-22 | 2006-07-06 | Shionogi & Co Ltd | メラニン凝集ホルモン受容体アンタゴニスト |
| WO2008046072A2 (en) * | 2006-10-13 | 2008-04-17 | The Board Of Regents Of The University Of Texas System | Chemical inducers of neurogenesis |
-
2006
- 2006-12-27 KR KR1020060135390A patent/KR101394245B1/ko not_active Expired - Fee Related
- 2006-12-28 WO PCT/KR2006/005837 patent/WO2007078113A1/en not_active Ceased
- 2006-12-28 EP EP06835537.9A patent/EP1971600B1/en not_active Not-in-force
- 2006-12-28 US US12/159,718 patent/US7915297B2/en not_active Expired - Fee Related
- 2006-12-28 JP JP2008548427A patent/JP5246499B2/ja active Active
- 2006-12-28 ES ES06835537T patent/ES2436103T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009522255A5 (enExample) | ||
| JP2013519680A5 (enExample) | ||
| EP2382212B1 (en) | Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases | |
| JP4972690B2 (ja) | 脂質レベルの上昇に関連する疾病の処置に適するヘテロ環式化合物 | |
| EP2592071B1 (en) | Tricyclic heterocyclic compounds | |
| JP2008526866A5 (enExample) | ||
| JP2009525984A5 (enExample) | ||
| JP2013505901A5 (enExample) | ||
| JP2002513424A (ja) | チアジアゾリルおよびオキサジアゾリルフェニルオキサゾリジノン抗菌剤 | |
| JP2004535466A5 (enExample) | ||
| WO2003093248A1 (en) | Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors | |
| JP2014500322A5 (enExample) | ||
| JP2015509510A5 (enExample) | ||
| ES2533095T3 (es) | Agonistas de receptores de esfingosina-1-fosfato | |
| JP2010521471A5 (enExample) | ||
| CN107922316A (zh) | Fto抑制剂 | |
| HRP20191554T1 (hr) | Derivat azol benzena | |
| EP2560969B1 (en) | 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists | |
| CN103102322B (zh) | 噁唑类化合物及其制备方法、药物组合物及其用途 | |
| WO2012040532A1 (en) | Substituted oxadiazole compounds and their use as s1p1 agonists | |
| RU2013133280A (ru) | Новые производные биариламидов | |
| CA2902135A1 (en) | Azetidine amide derivatives as orexin receptor antagonists | |
| JP2007532500A (ja) | フェニルチオ酢酸誘導体およびその使用 | |
| AU2012208325B2 (en) | 2-methoxy-pyridin-4-yl derivatives | |
| JP2007531763A5 (enExample) |